| 49228-0 |
Porphobilinogen deaminase |
CCnt |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Porphobilinogen deaminase [Enzymatic activity/mass] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
mU/g Hb |
|
|
|
|
|
|
CHEM |
|
49228-0 |
|
|
|
|
Both |
|
|
|
0 |
PBG Deaminase RBC-cCnt |
|
|
|
N |
|
Catalytic Content; Chemistry; Erythrocytes; Hematology; Heme; Hydroxymethylbilane Synthase; PBG; PBG Deaminase; PBGD; PBG-D; Point in time; Porph; Porphobili; Porphoblngn; Porpoblngn; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles; Uroporphyrinogen I Synthase |
2.73 |
2.21 |
|
|
|
|
|
|
|
mU/g{Hb} |
|
|
|
0 |
| 49229-8 |
Erythrocytes.nucleated/Leukocytes |
Ratio |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Nucleated erythrocytes/Leukocytes [Ratio] in Body fluid |
|
NAM |
DefinitionDescription |
|
|
/100 WBC |
|
|
|
|
|
|
HEM/BC |
|
49229-8 |
|
|
|
|
Both |
|
|
|
0 |
nRBC Fld-Rto |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Discocytes; Erthrocyte; Erythroblasts; Erythrocyte; Fl; Fld; FLU; Fluid; HEMATOLOGY/CELL COUNTS; Leuc; Leuk; Leukocyte; Lkcs; Normoblasts; nRBC; nRBCs; Nuc; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; RBC; RBCS; Red blood cell; Red blood cells; Red blood corpuscle; Red blood corpusles; Red cell; Red cells; Rto; WBC; WBCs; White blood cell; White blood cells |
2.79 |
2.21 |
|
|
|
|
|
|
|
/100{WBCs} |
|
|
Release 2.79: COMPONENT: Triggered by Coll w SCT: This is a specific fraction case where the denominator is percentage or /100. Because the logic is that the percentage piece is captured by Property: NFr (Numeric Fraction), and by Unit: %, therefore, it is redundant to include "100" in the component; |
0 |
| 4923-9 |
HLA-DPw2 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-DPw2 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4923-9 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-DPw2 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49230-6 |
Acetylcholinesterase |
CCnt |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Acetylcholinesterase [Enzymatic activity/mass] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
U/g Hb |
|
|
|
|
|
|
CHEM |
|
49230-6 |
|
|
|
|
Both |
|
|
|
0 |
AChE RBC-cCnt |
|
|
|
N |
|
Acetycholinesterase; Acetylcholine acetylhydrolase; Acetylhydrolase; AChE; ACLE; Catalytic Content; Chemistry; Choline esterase I; Cholinesterase true; Erythrocyte cholinesterase; Erythrocytes; Point in time; QNT; Quan; Quant; Quantitative; Random; RBC cholinesterase; Red blood cells; Red blood corpusles |
2.73 |
2.21 |
|
|
|
|
|
|
|
U/g{Hb} |
|
|
|
0 |
| 49231-4 |
Cholinesterase |
CCnt |
RBC |
Pt |
Qn |
|
|
ACTIVE |
Cholinesterase [Enzymatic activity/mass] in Red Blood Cells |
|
MIN |
DefinitionDescription |
|
|
U/g Hb |
|
|
|
|
|
|
CHEM |
|
49231-4 |
|
|
|
|
Both |
|
|
|
0 |
Cholinesterase RBC-cCnt |
|
|
|
N |
|
Acylcholine acylhydrolase; BChE; Benzoyl cholinesterase; Benzoylcholinesterase; Butyrylcholine esterase; Catalytic Content; Che; Chemistry; Choline esterase II; CHS; Erythrocytes; Point in time; Pseudocho; Pseudocholinesterase; QNT; Quan; Quant; Quantitative; Random; Red blood cells; Red blood corpusles |
2.73 |
2.21 |
|
|
|
|
|
|
|
U/g{Hb} |
|
|
|
0 |
| 49232-2 |
Giardia lamblia+Cryptosporidium sp Ag |
PrThr |
Stool |
Pt |
Ord |
Rapid, less than 30 minutes |
|
ACTIVE |
Giardia lamblia+Cryptosporidium sp Ag [Presence] in Stool by Rapid, less than 30 minutes |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49232-2 |
|
Rapid, less than 30 minutes |
|
|
Both |
|
|
|
0 |
G lamblia+Cryptosp Ag Stl Ql Rapid |
|
|
|
N |
|
Antigen; Antigens; Beaver fever; Bowel movement; Crypt; Crypto; Cryptosporidiosis; Faecal; Faeces; Fecal; Feces; G duodenalis; G intestinalis; G lamblia; G lamblia+Cryptosp; G lamblia+Cryptosp Ag; Giardiasis; ID; Infectious Disease; InfectiousDisease; Lamblia intestinalis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Rapid test; Screen; species; spp; Stl; Stool = Fecal |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49233-0 |
Giardia lamblia+Cryptosporidium parvum Ag |
PrThr |
Stool |
Pt |
Ord |
Rapid, less than 30 minutes |
|
ACTIVE |
Giardia lamblia+Cryptosporidium parvum Ag [Presence] in Stool by Rapid, less than 30 minutes |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
49233-0 |
|
Rapid, less than 30 minutes |
|
|
Both |
|
|
|
0 |
G lamblia+C parvum Ag Stl Ql Rapid |
|
|
|
N |
|
Antigen; Antigens; Beaver fever; Bowel movement; C parvum; Crypt; Crypto; Cryptosporidiosis; Faecal; Faeces; Fecal; Feces; G duodenalis; G intestinalis; G lamblia; G lamblia+C parvum; G lamblia+C parvum Ag; Giardiasis; ID; Infectious Disease; InfectiousDisease; Lamblia intestinalis; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Rapid test; Screen; Stl; Stool = Fecal |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49234-8 |
Patient symptoms^1.5H post dose lactose PO |
Imp |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Patient symptoms [Interpretation] Narrative--1.5 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49234-8 |
|
|
|
|
Observation |
|
|
|
0 |
Symptoms 1.5h p Lac PO Patient-Imp |
|
|
|
N |
|
1 1/2 hours; 1 1/2 HR; 1.5h p Lac PO; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LTT; Narrative; p dose; Point in time; PST; Random; Report; Sx |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49235-5 |
Patient symptoms^1H post dose lactose PO |
Imp |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Patient symptoms [Interpretation] Narrative--1 hour post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49235-5 |
|
|
|
|
Observation |
|
|
|
0 |
Symptoms 1h p Lac PO Patient-Imp |
|
|
|
N |
|
1 hour; 1.0Hr; 1h p Lac PO; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LTT; Narrative; p dose; Point in time; PST; Random; Report; Sx |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49236-3 |
Patient symptoms^2.5H post dose lactose PO |
Imp |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Patient symptoms [Interpretation] Narrative--2.5 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49236-3 |
|
|
|
|
Observation |
|
|
|
0 |
Symptoms 2.5h p Lac PO Patient-Imp |
|
|
|
N |
|
2.5h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LTT; Narrative; p dose; Point in time; PST; Random; Report; Sx |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49237-1 |
Patient symptoms^2H post dose lactose PO |
Imp |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Patient symptoms [Interpretation] Narrative--2 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49237-1 |
|
|
|
|
Observation |
|
|
|
0 |
Symptoms 2h p Lac PO Patient-Imp |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LTT; Narrative; p dose; Point in time; PST; Random; Report; Sx |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49238-9 |
Patient symptoms^30M post dose lactose PO |
Imp |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Patient symptoms [Interpretation] Narrative--30 minutes post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49238-9 |
|
|
|
|
Observation |
|
|
|
0 |
Symptoms 30M p Lac PO Patient-Imp |
|
|
|
N |
|
30M p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LTT; Narrative; p dose; Point in time; PST; Random; Report; Sx |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49239-7 |
Patient symptoms^3H post dose lactose PO |
Imp |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Patient symptoms [Interpretation] Narrative--3 hours post dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49239-7 |
|
|
|
|
Observation |
|
|
|
0 |
Symptoms 3h p Lac PO Patient-Imp |
|
|
|
N |
|
3h p Lac PO; After; CHEMISTRY.CHALLENGE TESTING; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LTT; Narrative; p dose; Point in time; PST; Random; Report; Sx |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 4924-7 |
HLA-DPw3 |
PrThr |
Bld/Tiss^Donor |
Pt |
Ord |
|
|
ACTIVE |
HLA-DPw3 [Presence] in Donor |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4924-7 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-DPw3 Donr Ql |
|
|
|
|
|
Blood; Donr; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld^donor' to 'Bld/Tiss^donor' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 49240-5 |
Patient symptoms^pre dose lactose PO |
Imp |
^Patient |
Pt |
Nar |
|
|
ACTIVE |
Patient symptoms [Interpretation] Narrative--pre dose lactose PO |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49240-5 |
|
|
|
|
Observation |
|
|
|
0 |
Symptoms pre Lac PO Patient-Imp |
|
|
|
N |
|
Before; CHEMISTRY.CHALLENGE TESTING; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; LTT; Narrative; Point in time; pre Lac PO; Random; Report; Sx |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49241-3 |
Xylose absorption |
Imp |
Urine+Ser/Plas |
Pt |
Nar |
|
|
ACTIVE |
Xylose absorption [Interpretation] in Urine and Serum or Plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHAL |
|
49241-3 |
|
|
|
|
Observation |
|
|
|
0 |
Xylose Absorption Ur+SerPl-Imp |
|
|
|
N |
|
Absorp; CHEMISTRY.CHALLENGE TESTING; D-xylose; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Pl; Plasma; Plsm; Point in time; Random; Report; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UA; UR; Ur+SerPl; Urn; Xylose absorption test |
2.38 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49242-1 |
Acylcarnitine pattern |
Imp |
Urine |
Pt |
Nar |
|
|
ACTIVE |
Acylcarnitine pattern [Interpretation] in Urine Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49242-1 |
|
|
|
|
Observation |
|
|
|
0 |
Acylcarnitine pattern Ur-Imp |
|
|
|
N |
|
Acyl carnitine; Acylcarni; Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Point in time; Random; Report; UA; UR; Urn |
2.26 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49243-9 |
Alkaline phosphatase isoenzymes |
Imp |
Ser/Plas |
Pt |
Nar |
|
|
ACTIVE |
Alkaline phosphatase isoenzymes [Interpretation] in Serum or Plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49243-9 |
|
|
|
|
Observation |
|
|
|
0 |
ALP Isos SerPl-Imp |
|
|
|
N |
|
Alk; Alk phos; Alkaline phos; Alkaline phosphatase.total; ALKP; ALP; ALP Isos; AP; Chemistry; Hepatology; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; ISO; Isoen; Isoenzyme; Liver; Narrative; Phos; Phosphtase; Pl; Plasma; Plsm; Point in time; Random; Report; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49244-7 |
Alpha 1 antitrypsin phenotype |
Imp |
Ser/Plas |
Pt |
Nar |
|
|
ACTIVE |
Alpha 1 antitrypsin phenotype [Interpretation] in Serum or Plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49244-7 |
|
|
|
|
Observation |
|
|
|
0 |
A1AT Phenotyp SerPl-Imp |
|
|
|
N |
|
A1; A1A; A1AT; A-1-AT; A1-AT; A1AT Phenotyp; AAT; Alfa; Alpha-1-antitrypsin.total; Alpha-1-protease inhibitor; Alpha-1-proteinase inhibitor; Alpha-1-trypsin inhibitor; Chemistry; Hepatology; i; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Liver; Lung; Narrative; Pl; Plasma; Plsm; Point in time; Pulmonary; Pulmonology; Random; Report; Respiratory; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
Release 2.71: COMPONENT: Changed for naming consistency across LOINC.; |
0 |
| 49245-4 |
Alpha tocopherol & Beta+gamma tocopherol |
Imp |
Ser/Plas |
Pt |
Nar |
|
|
ACTIVE |
Alpha tocopherol and Beta+gamma tocopherol [Interpretation] in Serum or Plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49245-4 |
|
|
|
|
Observation |
|
|
|
0 |
A & B+G Tocopherol SerPl-Imp |
|
|
|
N |
|
A & B+G Tocopherol; Alfa; A-Tocopherol Vit E; B; Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Pl; Plasma; Plsm; Point in time; Random; Report; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tocopherols; Vit E; Vitamin E |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49246-2 |
Alpha-1-Fetoprotein interpretation |
Imp |
Ser/Plas |
Pt |
Nar |
|
|
ACTIVE |
Alpha-1-Fetoprotein interpretation in Serum or Plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49246-2 |
|
|
|
|
Observation |
|
|
|
0 |
AFP Interp SerPl-Imp |
|
|
|
N |
|
A1; AFP; AFP Interp; Alfa; Alpha fetoprotein; Alphafetoprotein; Chemistry; Feto; i; Impression; Impression/interpretation of study; Impressions; Interp; Interpret; Interpretation; Interpt; Intrp; Narrative; Pl; Plasma; Plsm; Point in time; Random; Report; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49247-0 |
Amino acid pattern |
Imp |
Ser/Plas |
Pt |
Nar |
|
|
ACTIVE |
Amino acid pattern [Interpretation] in Serum or Plasma Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49247-0 |
|
|
|
|
Observation |
|
|
|
0 |
Amino acid Pat SerPl-Imp |
|
|
|
N |
|
Acd; Acids; Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Pl; Plasma; Plsm; Point in time; Random; Report; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49248-8 |
Amino acid pattern |
Imp |
Urine |
Pt |
Nar |
|
|
ACTIVE |
Amino acid pattern [Interpretation] in Urine Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49248-8 |
|
|
|
|
Observation |
|
|
|
0 |
Amino acid Pat Ur-Imp |
|
|
|
N |
|
Acd; Acids; Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Point in time; Random; Report; UA; UR; Urn |
2.73 |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 49249-6 |
Amino acids |
Imp |
Ser/Plas |
Pt |
Nar |
|
|
DEPRECATED |
Deprecated Amino acids [interpretation] in Serum or Plasma Narrative |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
49249-6 |
|
|
|
|
Observation |
|
|
|
0 |
Deprecated Amino acids SerPl-Imp |
|
|
|
N |
|
AA; Acd; Acid; Amino acid; Amino acids.total; Chemistry; Impression; Impression/interpretation of study; Impressions; Interp; Interpretation; Narrative; Pl; Plasma; Plsm; Point in time; Random; Report; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.48 |
2.21 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 4925-4 |
HLA-DPw3 |
PrThr |
Bld/Tiss |
Pt |
Ord |
|
|
ACTIVE |
HLA-DPw3 [Presence] |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
HLA |
|
4925-4 |
|
|
|
|
Observation |
|
|
|
0 |
HLA-DPw3 Ql |
|
|
|
|
|
Blood; Genetics; Heredity; Heritable; HLA ANTIGEN; Human Leukocyte Antigen; Inherited; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.56 |
1 |
|
|
|
|
|
|
|
|
|
|
This test is commonly performed on cells found in saliva and buccal swabs as well as blood specimens. Changed specimen from 'Bld' to 'Bld/Tiss' to represent both specimen types.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
